P

Inventor

VALENZUELA DAVID M

US87 patents
⚠️ This page may combine multiple inventors who share the name “VALENZUELA DAVID M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

44 patents
US6586251B2Jul 1, 2003

Methods of modifying eukaryotic cells

REGENERON PHARMA505 citations99
US9228208B2Jan 5, 2016

Methods and compositions for the targeted modification of a genome

REGENERON PHARMA79 citations98
US8697851B2Apr 15, 2014

MiRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA91 citations98
US7659442B2Feb 9, 2010

Method for making homozygous genetic modifications

REGENERON PHARMA239 citations98
US7576259B2Aug 18, 2009

Method for making genetic modifications

REGENERON PHARMA236 citations98
US7294754B2Nov 13, 2007

Method for generating an animal homozygous for a genetic modification

REGENERON PHARMA445 citations98
US7205148B2Apr 17, 2007

Genome mutation by intron insertion into an embryonic stem cell genome

REGENERON PHARMA93 citations98
US8354389B2Jan 15, 2013

miRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA56 citations97
US10385359B2Aug 20, 2019

Targeted modification of rat genome

REGENERON PHARMA29 citations94
US10208317B2Feb 19, 2019

Methods and compositions for the targeted modification of a mouse embryonic stem cell genome

REGENERON PHARMA15 citations94
US9546384B2Jan 17, 2017

Methods and compositions for the targeted modification of a mouse genome

REGENERON PHARMA31 citations94
US10329582B2Jun 25, 2019

Genetic modification of rats

REGENERON PHARMA25 citations93
US9708635B2Jul 18, 2017

Methods of making a nucleic acid encoding a human variable region

REGENERON PHARMA9 citations93
US9388446B2Jul 12, 2016

Methods of producing hybrid antibodies

REGENERON PHARMA6 citations93
US9371553B2Jun 21, 2016

Genetically modified mice that produce hybrid antibodies

REGENERON PHARMA6 citations93
US9353394B2May 31, 2016

Methods of producing hybrid antibodies

REGENERON PHARMA6 citations93
US8846402B2Sep 30, 2014

Method for genetically modifying isolated non-human mammalian cell by homologous recombination

REGENERON PHARMA17 citations93
US10039269B2Aug 7, 2018

Methods and compositions for generating a mouse

REGENERON PHARMA10 citations92
US9730434B2Aug 15, 2017

Methods and compositions for generating a mouse

REGENERON PHARMA11 citations92
US9414575B2Aug 16, 2016

Methods and compositions for generating a mouse

REGENERON PHARMA12 citations92
US8946505B2Feb 3, 2015

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA10 citations92
US8946504B2Feb 3, 2015

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA10 citations92
US6852838B2Feb 8, 2005

Tyrosine kinase receptors and ligands

REGENERON PHARMA15 citations92
US5851797ADec 22, 1998

Tie ligand-3, methods of making and uses thereof

REGENERON PHARMA26 citations92
US5814478ASep 29, 1998

Tyrosine kinase receptors and ligands

REGENERON PHARMA20 citations92
US9738897B2Aug 22, 2017

Nuclease-mediated DNA assembly

REGENERON PHARMA13 citations91
US6610510B1Aug 26, 2003

Morphogenic proteins

REGENERON PHARMA20 citations91
US10711280B2Jul 14, 2020

Methods and compositions for the targeted modification of a mouse ES cell genome

REGENERON PHARMA5 citations84
US10640800B2May 5, 2020

Mice that produce hybrid antibodies

REGENERON PHARMA4 citations84
US10526630B2Jan 7, 2020

Genetically modified mice that produce hybrid antibodies

REGENERON PHARMA3 citations84
US10378038B2Aug 13, 2019

Mice that produce hybrid antibodies

REGENERON PHARMA3 citations84
US10378039B2Aug 13, 2019

Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus

REGENERON PHARMA3 citations84
US10378040B2Aug 13, 2019

Mice that produce hybrid antibodies

REGENERON PHARMA4 citations84
US10378037B2Aug 13, 2019

Methods of making a nucleic acid encoding a human variable region

REGENERON PHARMA3 citations84
US10301646B2May 28, 2019

Nuclease-mediated targeting with large targeting vectors

REGENERON PHARMA12 citations84
US10227625B2Mar 12, 2019

Methods of modifying eukaryotic cells

REGENERON PHARMA3 citations84
US9834786B2Dec 5, 2017

Nuclease-mediated targeting with large targeting vectors

REGENERON PHARMA13 citations84
US9528136B2Dec 27, 2016

Methods of modifying eukaryotic cells

REGENERON PHARMA5 citations84
US9410163B2Aug 9, 2016

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA3 citations84
US9382567B2Jul 5, 2016

Methods of producing hybrid antibodies

REGENERON PHARMA3 citations84
US10106820B2Oct 23, 2018

Methods and compositions for modifying a targeted locus

REGENERON PHARMA6 citations83
US9902971B2Feb 27, 2018

Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation

REGENERON PHARMA5 citations83
US9267152B2Feb 23, 2016

MiRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA4 citations83
US9096870B2Aug 4, 2015

miRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA6 citations83

MURPHY ANDREW J

2 patents

ECONOMIDES ARIS N

1 patent

FRENDEWEY DAVID

1 patent

POUEYMIROU WILLIAM

1 patent

ONCOGENE SCIENCE INC

1 patent

Showing the top 50 of 87 patents by PatentIndex Score.